Jeffrey Stamp, MD
Family Medicine · Cabot, ARNPI 1023079985
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 79 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $350 and has fallen 90.2% since, to $34 in 2025.
Across 79 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$219
- Amgen$210
- Novo Nordisk$143
- Amarin Pharma, Inc.$85
- Lilly USA, LLC$71
- Merck$65
- plus $482 from 18 others
What the payments were for
- Food & beverage$1,275100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 15 | $219 |
| Amgen(2 entities) | 13 | $210 |
| Novo Nordisk | 10 | $143 |
| Amarin Pharma, Inc. | 5 | $85 |
| Lilly USA, LLC | 2 | $71 |
| Merck | 4 | $65 |
| Bausch Health US, LLC | 3 | $58 |
| Eisai Inc. | 4 | $58 |
| AbbVie(2 entities) | 3 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $42 |
| Sanofi Pasteur Inc. | 2 | $36 |
| Boston Scientific | 1 | $34 |
| Ironshore Pharmaceuticals Inc. | 2 | $29 |
| Johnson & Johnson | 2 | $25 |
| Abbott | 1 | $25 |
| Strongbridge US Inc. | 1 | $18 |
| Corium, LLC | 1 | $18 |
| AstraZeneca | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Dexcom, Inc. | 1 | $11 |
How this compares
$1,275 in reported general payments places this provider in the 60th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 15 | $93 |
| Hydrochlorothiazide | 12 | $26 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Cabot
- Glenn GibbonsFort Smith$179K
- Hetal PatelParagould$147K
- David GersonSherwood$119K
- Scott MusickBentonville$102K
- Broderick EatonWynne$49K
- Craig LevoyBentonville$30K
- Allen BeachyFort Smith$21K
- Hunter CarringtonHot Springs$20K
- Harold BettonLittle Rock$18K
- Thad HardinConway$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.